1
|
|
Chapter 1 The strategic biomarker roadmap for the validation of Alzheimer’s
diagnostic biomarkers: methodological update
Marina Boccardi1,2 & Alessandra Dodich3,4 & Emiliano Albanese5 & Angèle Gayet-Ageron6 & Cristina Festari7 & Nicholas J. Ashton8,9,10,11 & Gérard N. Bischof12 & Konstantinos Chiotis13,14 & Antoine Leuzy13 & Emma E. Wolters15 & Martin A. Walter16 & Gil D. Ra
PDF (0 KB)
|
|
|
|
17
|
|
Chapter 2 Effect of oxaliplatin plus 5-fluorouracil or
capecitabine on circulating and imaging
biomarkers in patients with metastatic
colorectal cancer: a prospective biomarker
study
Reem D. Mahmood1*† , Danielle Shaw2†, Tine Descamps3, Cong Zhou3, Robert D. Morgan1,4, Saifee Mullamitha1, Mark Saunders1, Nerissa Mescallado1, Alison Backen1,4, Karen Morris3, Ross A. Little4, Susan Cheung4, Yvonne Watson4, James P. B. O’Connor1,4, Alan J
PDF (0 KB)
|
|
|
|
25
|
|
Chapter 3 Diagnostic biomarker kinetics:
how brain‑derived biomarkers distribute
through the human body, and how this affects
their diagnostic significance: the case of S100B
Robert Murcko1, Nicola Marchi3, Damian Bailey4 and Damir Janigro1,2*
PDF (0 KB)
|
|
|
|
45
|
|
Chapter 4 Estimated glucose disposal rate as a candidate biomarker
for thrombotic biomarkers in T1D: a pooled analysis
L. L. O’Mahoney1,2 · N. Kietsiriroje3 · S. Pearson4 · D. J. West5,6 · M. Holmes7 · R. A. Ajjan4 · M. D. Campbell4,8,9
PDF (0 KB)
|
|
|
|
55
|
|
Chapter 5 Why did European Radiology reject my radiomic biomarker paper?
How to correctly evaluate imaging biomarkers in a clinical setting
Steve Halligan1 & Yves Menu2 & Sue Mallett1
PDF (0 KB)
|
|
|
|
63
|
|
Chapter 6 Plasma biomarkers TAP, CPA1, and CPA2 for the detection of pancreatic
injury in rat: the development of a novel multiplex IA‑LC‑MS/MS assay
and biomarker performance evaluation
Katerina Vlasakova1 · Andreas Steinhilber2 · Wendy J. Bailey1 · Zoltan Erdos1 · Hanna Haag2 · Thomas Joos2,3 · Bradley L. Ackermann4 · Oliver Poetz2,3 · Warren E. Glaab1
PDF (0 KB)
|
|
|
|
80
|
|
Chapter 7 Study design for development of novel
safety biomarkers of drug‑induced liver injury
by the translational safety biomarker pipeline
(TransBioLine) consortium: a study protocol
for a nested case–control study
Jane I. Grove1,2† , Camilla Stephens3,4† , M. Isabel Lucena3,4 , Raúl J. Andrade3,4 , Sabine Weber5, Alexander Gerbes5 , Einar S. Bjornsson6,7 , Guido Stirnimann8 , Ann K. Daly9 , Matthias Hackl10 , Kseniya Khamina‑Kotisch10 , Jose J. G. Marin4,11, Maria J
PDF (0 KB)
|
|
|
|
95
|
|
Chapter 8 Biomarker heatmaps: visualization of complex biomarker data to
detect storm-induced source changes in fluvial particulate organic
carbon
Jieun Kim1 · Neal E. Blair
PDF (0 KB)
|
|
|
|
105
|
|
Chapter 9 The Biomarker Toolkit — an evidence‑based
guideline to predict cancer biomarker success
and guide development
Katerina‑Vanessa Savva1*, Michal Kawka1, Bhamini Vadhwana1, Rahul Penumaka1, Imogen Patton1, Komal Khan1, Claire Perrott1, Saranya Das1, Maxime Giot1, Stella Mavroveli1, George B. Hanna1, Melody Zhifang Ni1 and Christopher J. Peters1
PDF (0 KB)
|
|
|
|
114
|
|
Chapter 10 Functional principal component analysis
and sparse‑group LASSO to identify associations
between biomarker trajectories and mortality
among hospitalized SARS‑CoV‑2 infected
individuals
Tingyi Cao1*, Harrison T. Reeder2,3 and Andrea S. Foulkes1,2,3
PDF (0 KB)
|
|
|
|